Abstract Background: In the European Union (EU) and neighbouring countries, HIV/AIDS, of
all infectious diseases, has one of the highest morbidity and mortality rates. An estimated …

A substantial proportion of HIV-infected individuals do not present for HIV testing until late in
infection; these individuals are often ill, have a high mortality risk, and are less likely to …

Background An increasing proportion of deaths among human immunodeficiency virus (HIV)–
infected persons with access to combination antiretroviral therapy (cART) are due to …

Background Few studies have monitored late presentation (LP) of HIV infection over the
European continent, including Eastern Europe. Study objectives were to explore the impact …

Mucosal-associated invariant T (MAIT) cells are an evolutionarily conserved antimicrobial
MR1-restricted T-cell subset. MAIT cells are CD161+, express a Vα7. 2 TCR, are primarily …

Background Optimal timing of ART initiation for individuals presenting with AIDS-related OIs
has not been defined. Methods and Findings A5164 was a randomized strategy trial of “early …

Mucosa-associated invariant T (MAIT) cells represent a large innate-like evolutionarily
conserved antimicrobial T-cell subset in humans. MAIT cells recognize microbial riboflavin …

Objectives: To assess the incidence and spectrum of AIDS-defining opportunistic illnesses in
the highly active antiretroviral therapy (cART) era. Design: A prospective cohort study of …

Background. There are few recent data on the rates of AIDS-defining opportunistic infections
(OIs) among human immunodeficiency virus (HIV)–infected patients in care in the United …

Objective: Present 96-week data from ongoing ARTEMIS (AntiRetroviral Therapy with
TMC114 ExaMined In Naive Subjects) trial. Methods: Randomized, open-label, phase III trial …